Sigma HealthcareASX:SIG -1.07%59 EBITDA Margin % is 11.47% as of Dec. 2025, which is 555% above its 10-year median of 1.75. GuruFocus rates ASX:SIG with a GF Score™ of 59/100 and a GF Value™ of A$0.37 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 119 Medical Distribution companies, Sigma Healthcare ranks better than 64.71% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Sigma Healthcare's EBITDA for the
six
months ended in Dec. 2025 was A$607 Mil. Sigma Healthcare's Revenue for the
six
months ended in Dec. 2025 was A$5,294 Mil. Therefore, Sigma Healthcare's EBITDA margin for the quarter that ended in Dec. 2025 was 11.47%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Sigma Healthcare EBITDA Margin % Related Terms
Sigma Healthcare EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Sigma Healthcare's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:SIG vs MCK, COR, CAH: EBITDA Margin % Comparison
For the Medical Distribution subindustry, Sigma Healthcare's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sigma Healthcare EBITDA Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sigma Healthcare's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Sigma Healthcare's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sigma Healthcare (ASX:SIG) has a EBITDA Margin % of 11.47% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sigma Healthcare and its competitors. This is 555% above median its historical median of 1.75. Over the past decade, Sigma Healthcare's EBITDA Margin % has ranged from 0.76 to 7.69. According to the industry distribution chart, Sigma Healthcare ranks #42 out of 119 companies in the Medical Distribution industry, placing it in the top 35.3%.
Is Sigma Healthcare's EBITDA Margin % too high?
Sigma Healthcare's current EBITDA Margin % of 11.47% is 555% above median its 10-year median of 1.75. Over the past 10 years, this metric has ranged from a low of 0.76 to a high of 7.69. The Medical Distribution industry median EBITDA Margin % is 4.31. Sigma Healthcare's value of 11.47% is 166.1% above this industry median. Based on the distribution chart, Sigma Healthcare ranks #42 out of 119 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Sigma Healthcare has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sigma Healthcare's EBITDA Margin % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Sigma Healthcare ranks #42 out of 119 companies for EBITDA Margin %. This puts Sigma Healthcare in the upper half of its industry. The industry median EBITDA Margin % is 4.31. Sigma Healthcare's value of 11.47% is 166.1% above this benchmark. Historically, Sigma Healthcare's own EBITDA Margin % has ranged from 0.76 to 7.69 over the past decade. While the company's 10-year median is 1.75 vs. the industry median of 4.31, Sigma Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Distribution company?
The median EBITDA Margin % among Medical Distribution companies is 4.31, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sigma Healthcare's current EBITDA Margin % of 11.47% is 166.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sigma Healthcare and its competitors. For the Medical Distribution industry, the median EBITDA Margin % is 4.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sigma Healthcare's current EBITDA Margin % is 11.47%, which is 555% above median its own 10-year median of 1.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sigma Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Sigma Healthcare (ASX:SIG) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.37, compared to a current price of A$2.77 — trading 648.6% above its estimated fair value. The current EBITDA Margin % is 11.47%, which is 555% above median its 10-year median of 1.75 and 166.1% above the Medical Distribution industry median of 4.31. Sigma Healthcare's overall GF Score™ is 59/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Sigma Healthcare (ASX:SIG), the current EBITDA Margin % is 11.47% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sigma Healthcare (ASX:SIG) Overvalued in 2026?
Based on GuruFocus' analysis, Sigma Healthcare stock appears to be overvalued.
The current stock price of A$2.77 is trading 648.6% above its estimated GF Value™ of A$0.37.
GuruFocus considers Sigma Healthcare to be Significantly Overvalued.
Key valuation signals for ASX:SIG:
EBITDA Margin %: 11.47% (555% above median its 10-year median of 1.75)
GF Value™: A$0.37 vs. price of A$2.77 (648.6% above fair value)
Industry Position: 166.1% above the Medical Distribution median (#42 of 119)
No single metric tells the full story. See the ASX:SIG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sigma Healthcare is Australia's largest retail pharmacy franchisor, most notably owning the Chemist Warehouse brand, which it merged with in 2025. Sigma is also Australia's largest full-line wholesaler to franchised and independent pharmacies and distributes a broad range of pharmacy products, including prescription medicines, over-the-counter products, and front of store, or FOS, products, at low prices. The group also operates in New Zealand, Ireland, China, and Dubai, has a growing private label range, and offers third-party logistics services.
59GF Score
Get the complete analysis for ASX:SIG
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:SIG has been successfully added to your 
